GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to new employees. On July 1, 2024, the Company issued to these employees options to purchase an aggregate of 35,198 shares of the Company’s common stock with an exercise price of $24.27, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant.

马里兰州盖瑟斯堡，2024年7月8日（环球通讯社）--Cartesian Therapeutics，Inc.（纳斯达克：RNAC）（“公司”）是一家临床阶段的生物技术公司，开发用于治疗自身免疫性疾病的mRNA细胞疗法，今天宣布向新员工授予诱导奖。。

The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. Each of the options vest as to 25% on July 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on July 1, 2028.

期权是根据公司修订和重述的2018年就业激励奖励计划授予的，并得到了公司董事会的批准。每个期权在2025年7月1日授予25%，然后在此后的三个相等的年度分期付款中授予，这样期权将在2028年7月1日完全授予。

Each of the options has a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company..

每种期权的有效期均为十年。这些期权是根据《纳斯达克上市规则》第5635（c）（4）条授予的，作为该员工在公司就业的诱因材料。。

About Cartesian Therapeutics

关于笛卡尔疗法

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications.

Cartesian Therapeutics是一家临床阶段公司，开创了用于治疗自身免疫性疾病的mRNA细胞疗法。该公司的主要资产Descartes-08是针对全身性重症肌无力患者的2b期临床开发和系统性红斑狼疮的2期开发中潜在的一流mRNA CAR-T，计划在其他自身免疫适应症中进行2期篮式试验。

The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter..

该公司的临床阶段管道还包括下一代自体抗BCMA mRNA CAR-T Descartes-15。有关更多信息，请访问www.cartesiantherapeutics.com或在LinkedIn或X（以前称为Twitter）上关注该公司。。

Investor Contact

投资者联系人

Ron Moldaver

朗姆酒

Senior Director, Investor Relations & Business Development

投资者关系与业务发展高级总监

ron.moldaver@cartesiantx.com

ron.moldaver@cartesiantx.com

Media Contact

媒体联系人

David Rosen

戴维·罗森

Argot Partners

Argot合作伙伴

david.rosen@argotpartners.com

david.rosen@argotpartners.com